

**Table S1.** Antifungal susceptibility of *Candida* isolates to amphotericin B and caspofungin. %resistant: percentage of isolates resistant to antifungal.

<i>Candida</i> species	n	Amphotericin B				Caspofungin			
		Sensitive	intermediate	resistant	% resistant	n	sensitive	resistant	%resistant
<i>C. albicans</i>	20	20	0	0	0.0%	5	5	0	0.0%
<i>C. glabrata</i>	20	19	0	1	5.0%	5	5	0	0.0%
<i>C. tropicalis</i>	8	8	0	0	0.0%	2	2	0	0.0%
<i>C. parapsilosis</i>	5	5	0	0	0.0%	1	1	0	0.0%
<i>P. kudriavzevii</i> ( <i>C. krusei</i> )	2	2	0	0	0.0%	0	0	0	0.0%
<i>K. marxianus</i> ( <i>C. kefyr</i> )	2	2	0	0	0.0%	1	1	0	0.0%
<i>C. lusitanae</i>	1	0	1	0	0.0%	0	0	0	0.0%
Total	58	56	1	1	1.7%	14	14	0	0.0%

**Table S2.** Univariate analysis of possible risk factors associated with 30-day mortality. Data are presented as percentages unless otherwise specified. CLABSI: Central Line-Associated Bloodstream Infection. \*:p-values<0.05

Characteristic	Alive at 30 days	Dead at 30 days	p-value
Age (years, mean ± SD)	61.4 ± 18.6	70 ± 14.9	<b>0.002*</b>
Female	47.90	49.50	0.848
Year of admission			
	2004-2009	19.2	15.4
	2010-2014	45.2	30.8
	2015-2019	35.6	53.8
Critical care unit	27.4	64.8	<b>&lt;0.001*</b>
Diabetes mellitus	27.4	30.8	0.637
Hemodialysis patient	13.7	20.9	0.231
	End-stage renal disease	6.8	5.5
	Acute kidney injury	6.8	15.4
Solid organ transplant recipient	0.0	2.2	0.503
Stem cell transplant recipient	4.1	4.40	1.00
	Auto-transplant	33.3	50.0
	Allo-transplant	33.3	50.0
	Both	33.3	0.0
Neutropenic	6.8	17.6	<b>0.041*</b>
	1000-1500/mm <sup>3</sup>	20.0	12.5
	500-1000/mm <sup>3</sup>	0.0	37.5
	<500/mm <sup>3</sup>	80.0	50.0
Immunocompromised	56.2	70.3	0.060
Current steroids	16.4	25.3	0.170

Congenital syndromes		2.7	1.1	0.586
Other immunosuppressants		2.7	6.6	0.301
Malignancy		46.6	53.8	0.355
	Non-hematologic	23.5	24.5	
	Hematologic	73.5	69.4	0.926
	Both	2.9	6.1	
Chemotherapy		24.7	22.0	0.686
	<1 week from infection	33.3	20.0	0.468
Immunotherapy				
Abdominal surgery within 30 days		31.5	23.1	0.226
Antibiotics within 30 days		95.9	93.4	0.732
Antifungal history		23.3	28.6	0.445
	Fluconazole	19.2	18.7	0.936
	Voriconazole	1.4	1.1	1.00
	Amphotericin B	1.4	3.3	0.63
	Caspofungin	1.4	5.5	0.227
	Anidulafungin	0.0	2.2	0.503
Duration of previous antifungal (days, mean ± SD)		9.13 ± 12.2	16.7 ± 17.9	0.152
Parenteral nutrition		27.4	25.3	0.759
Central venous catheter		63.0	75.8	0.075
Source				
	CLABSI	27.4	19.8	0.251
	Gastrointestinal translocation	35.6	33.0	0.722
	Urinary tract infection	13.7	6.6	0.128
	Unknown	19.2	38.5	<b>0.007*</b>
	Other	1.4	1.1	1.00
Candida non-albicans		61.6	63.7	0.783
Echocardiography		63.0	46.2	<b>0.031*</b>
Ophthalmic exam		28.8	14.3	<b>0.023*</b>
Empiric therapy				
	Fluconazole	40.6	30.9	0.236
	Voriconazole	1.4	1.5	1.00
	Itraconazole	4.3	2.9	1.00
	Caspofungin	27.5	29.4	0.808
	Anidulafungin	7.2	19.1	<b>0.04*</b>
	Micafungin	10.1	8.8	0.792
	Lipid formulation of amphotericin B	8.7	7.4	0.772
Central venous catheter removed		91.3	53.6	<b>&lt;0.001*</b>
	Tip sent for culture	88.1	78.4	0.245